Fetal therapies and trials for lysosomal storage diseases: a survey of attitudes of parents and patients
Open Access
- 29 January 2022
- journal article
- research article
- Published by Springer Nature in Orphanet Journal of Rare Diseases
- Vol. 17 (1) , 1-11
Abstract
Background: Lysosomal storage diseases (LSDs) are inherited metabolic disorders that may lead to severe multi-organ disease. Current ERTs are limited by anti-drug antibodies, the blood–brain barrier, and early disease onset and progression before ERT is started. We have opened a phase I clinical trial of enzyme replacement therapy (ERT) for fetuses with LSDs (NCT04532047). We evaluated the attitudes of parents and patients with LSDs towards fetal clinical trials and therapies. Methods: A multidisciplinary team designed a survey which was distributed by five international patient advocacy groups. We collected patients’ demographic, diagnostic, and treatment information. Associations between respondent characteristics and attitudes towards fetal therapies/trials were analyzed using multivariate ordinal logistic regression. Results: The survey was completed by 181 adults from 19 countries. The majority of respondents were mothers from the United States. The most common diseases were MPS1 (26%), MPS3 (19%), and infantile-onset Pompe (14%). Most patients (88%) were diagnosed after birth, at a median of 21 months. Altogether, 65% of participating patients and children of participants had received ERT, 27% a stem cell transplant, and 4% gene therapy. We found that half (49%) of respondents were unlikely to terminate a future affected pregnancy, 55% would enroll in a phase I clinical trial for fetal ERT, and 46% would enroll in a fetal gene therapy trial. Respondents who received postnatal ERT were significantly more likely enroll in a trial for fetal ERT or gene therapy (ERT OR 4.48, 95% CI 2.13–9.44, p < 0.0001; gene therapy OR 3.03, 95% CI 1.43–6.43, p = 0.0038). Respondents who used clinicaltrials.gov as a main source of information were more likely to choose to participate in a fetal trial (ERT OR 2.43, 95% CI 1.18–5.01, p = 0.016; gene therapy OR 2.86, 95% CI 1.27–6.46, p = 0.011). Conclusions: Familiarity with postnatal ERT increased respondents’ likelihood of pursuing fetal therapies. Families who use clinicaltrials.gov may be more receptive to innovative fetal treatments. The patient community has a favorable attitude towards fetal therapy; over half of respondents would enroll in a phase I clinical trial to assess the safety and efficacy of fetal ERT.Keywords
Funding Information
- NIH (T32AI125222)
- UCSF Center for Maternal-Fetal Precision Medicine (TL1 TR001871)
This publication has 42 references indexed in Scilit:
- Illness Perception and Clinical Treatment Experiences in Patients with M. Maroteaux-Lamy (Mucopolysaccharidosis Type VI) and a Turkish Migration Background in GermanyPLOS ONE, 2013
- Design, baseline characteristics, and early findings of the MPS VI (mucopolysaccharidosis VI) Clinical Surveillance Program (CSP)Journal of Inherited Metabolic Disease, 2011
- Maternal T cells limit engraftment after in utero hematopoietic cell transplantation in miceJournal of Clinical Investigation, 2011
- Long-term Efficacy and Safety of Laronidase in the Treatment of Mucopolysaccharidosis IPediatrics, 2009
- A phase I/II clinical trial of enzyme replacement therapy in mucopolysaccharidosis II (Hunter syndrome)Molecular Genetics and Metabolism, 2007
- Can mucopolysaccharidosis type I disease severity be predicted based on a patient’s genotype? A comprehensive review of the literatureGenetics in Medicine, 2003
- In utero gene transfer of human factor IX to fetal mice can induce postnatal tolerance of the exogenous clotting factorBlood, 2003
- A comparison of disease and gene frequencies of inborn errors of metabolism among different ethnic groups in the West Midlands, UK.Journal of Medical Genetics, 1998
- Murine mucopolysaccharidosis type VII: long term therapeutic effects of enzyme replacement and enzyme replacement followed by bone marrow transplantation.Journal of Clinical Investigation, 1997
- The products of conception: the social context of reproductive choices.Journal of Medical Ethics, 1985